Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.
Key News
JULY 16, 2021
Our overdose rescue medication OX124 enters pivotal study
JULY 15, 2021
Announcement of the Q2 2021 Interim Report
JULY 12, 2021
Commercial partnership agreement signed with Sober Grid for vorvida® and deprexis®
Orexo Social
@OrexoABpubl
16 July 2021
NEWS: The pivotal study for our rescue medication OX124 has been initiated. A New Drug Application is expected to b… https://t.co/AobekYZrVv
@OrexoABpubl
15 July 2021
Q2 Interim Report – In O2 we saw increased activities in R&D and the DTx business. The greatest highlight was that… https://t.co/nLDmtFzEqz
@OrexoABpubl
12 July 2021
Today we announce a commercial partnership has been signed with @SoberGridApp the largest social media community fo… https://t.co/rgn1kjo6Tf
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
News Flow
Press Releases & News
Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo
Invitation to presentation of Orexo´s Q2 Interim Report, on July 15 at 3 pm CET
Financial Snapshot
Group net revenues
585 MSEK
LTM1
Group EBITDA
-76 MSEK
LTM1
US Pharma segment EBIT
295 MSEK
LTM1
Cash position
680 MSEK
Q1 2021
1 Last Twelve Months, Q320-Q221, for more information about financial development Link